Recent patents in allergy and immunology: A quantitative real‐time polymerase chain reaction method for diagnosing asthma and asthma exacerbation

Lee, Pureun‐Haneul; Choi, Seon-Muk; An, Min‐Hyeok; Jang, An‐Soo

doi:10.1002/clt2.12136

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported that the plasma proteins of cell barrier proteins, such as nectin-4, claudin-4, and claudin-5, were related to the exacerbation of obstructive lung disease, such as asthma, and chronic obstructive lung disease. 24 25 26 27 …”

Section: Discussionmentioning

confidence: 99%

Impact of the Junction Adhesion Molecule-A on Asthma

Lee

Choi

et al. 2023

Yonsei Med J

Self Cite

View full text Add to dashboard Cite

Purpose Junctional adhesion molecule (JAM)-A is an immunoglobulin-like molecule that colocalizes with tight junctions (TJs) in the endothelium and epithelium. It is also found in blood leukocytes and platelets. The biological significance of JAM-A in asthma, as well as its clinical potential as a therapeutic target, are not well understood. The aim of this study was to elucidate the role of JAM-A in a mouse model of asthma, and to determine blood levels of JAM-A in asthmatic patients. Materials and Methods Mice sensitized and challenged with ovalbumin (OVA) or saline were used to investigate the role of JAM-A in the pathogenesis of bronchial asthma. In addition, JAM-A levels were measured in the plasma of asthmatic patients and healthy controls. The relationships between JAM-A and clinical variables in patients with asthma were also examined. Results Plasma JAM-A levels were higher in asthma patients (n=19) than in healthy controls (n=12). In asthma patients, the JAM-A levels correlated with forced expiratory volume in 1 second (FEV 1 %), FEV 1 /forced vital capacity (FVC), and the blood lymphocyte proportion. JAM-A, phospho-JNK, and phospho-ERK protein expressions in lung tissue were significantly higher in OVA/OVA mice than in control mice. In human bronchial epithelial cells treated with house dust mite extracts for 4 h, 8 h, and 24 h, the JAM-A, phospho-JNK, and phospho-ERK expressions were increased, as shown by Western blotting, while the transepithelial electrical resistance was reduced. Conclusion These results suggest that JAM-A is involved in the pathogenesis of asthma, and may be a marker for asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the Junction Adhesion Molecule-A on Asthma

Lee

Choi

et al. 2023

Yonsei Med J

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nectin-4, a cell adhesion molecule, is also expressed in tracheal tissue and is involved in the spread of measles in the trachea [ 8 , 9 ]. Nectin-4 is also implicated in airway inflammation; some reports suggest it may be a potential therapeutic target in asthma [ 10 , 11 ]; thus, suggest that EV, which targets nectin-4, may trigger asthma exacerbations.…”

Section: Discussionmentioning

confidence: 99%

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Homma,

Tanaka,

Takeda

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that is recently being used in the management of patients with urothelial carcinoma. The common adverse events include rashes, peripheral neuropathy, and hyperglycemia. Only a few cases of associated respiratory symptoms have been reported. Herein, we describe 2 patients with advanced urothelial carcinoma who experienced asthma exacerbation after initiating enfortumab vedotin treatment. Both patients improved with inhalation therapy. Since nectin-4 is expressed in the tracheal epithelium, its association with asthma is likely. This study highlights that clinicians should caution patients with a history of asthma against the worsening of respiratory symptoms when enfortumab vedotin is administered.

show abstract

“…As well as these potential applications in cancer diagnosis, increased levels of soluble Nectin-4 in serum may contribute to the diagnosis and monitoring of asthma ( 62 ) and may also represent a new biomarker for opioid dependence ( 63 , 64 ). To date, most research has focused on Nectin-4 as a transmembrane protein of tumor cells, with less attention paid to soluble Nectin-4.…”

Section: Diagnostic Potential Of Nectin-4mentioning

confidence: 99%

Therapeutic prospects of nectin-4 in cancer: applications and value

Li,

Zhou,

Zang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Nectin-4 is a Ca2+-independent immunoglobulin-like protein that exhibits significantly elevated expression in malignant tumors while maintaining extremely low levels in healthy adult tissues. In recent years, overexpression of Nectin-4 has been implicated in tumor occurrence and development of various cancers, including breast cancer, urothelial cancer, and lung cancer. In 2019, the Food and Drug Administration approved enfortumab vedotin, the first antibody–drug conjugate targeting Nectin-4, for the treatment of urothelial carcinoma. This has emphasized the value of Nectin-4 in tumor targeted therapy and promoted the implementation of more clinical trials of enfortumab vedotin. In addition, many new drugs targeting Nectin-4 for the treatment of malignant tumors have entered clinical trials, with the aim of exploring potential new indications. However, the exact mechanisms by which Nectin-4 affects tumorigenesis and progression are still unclear, and the emergence of drug resistance and treatment-related adverse reactions poses challenges. This article reviews the diagnostic potential, prognostic significance, and molecular role of Nectin-4 in tumors, with a focus on clinical trials in the field of Nectin-4-related tumor treatment and the development of new drugs targeting Nectin-4.

show abstract

Recent patents in allergy and immunology: A quantitative real‐time polymerase chain reaction method for diagnosing asthma and asthma exacerbation

Cited by 4 publications

References 3 publications

Impact of the Junction Adhesion Molecule-A on Asthma

Impact of the Junction Adhesion Molecule-A on Asthma

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Therapeutic prospects of nectin-4 in cancer: applications and value

Contact Info

Product

Resources

About